Latest News

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...

It's not a stretch to say that Redox Limited's ( ASX:RDX ) price-to-earnings (or "P/E") ratio of 18.9x right now seems...

By buying an index fund, you can roughly match the market return with ease. But many of us dare to dream of bigger...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

The Inghams Group Limited ( ASX:ING ) share price has fared very poorly over the last month, falling by a substantial...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

Medacta Group SA recently reported strong half-year earnings, with sales reaching €344.14 million and net income rising to €60.04 million, while confirming 2025 guidance targeting 16% to 18% revenue growth in constant currency. Alongside these financial results, the company continued to expand its Personalized Sports Medicine Portfolio, launching the QuickStitch device at a major industry congress, highlighting ongoing investment in innovation and physician education. We'll examine how...

SPDR Gold Trust (GLD) is in focus after gold prices hit new all-time highs in 2025, with inflation and geopolitical worries drawing eyes to the yellow metal. Recent headlines highlight how gold-backed ETFs are becoming top choices for investors seeking secure, liquid access to bullion during times of uncertainty. For those considering whether to take action, GLD’s prominent liquidity and direct exposure to gold make it a leading name in this space. Amid this gold rally, SPDR Gold Trust has...

Whilst it may not be a huge deal, we thought it was good to see that the G8 Education Limited ( ASX:GEM ) Independent...

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Arteche Lantegi Elkartea (BME:ART) Surprises With Strong Earnings Growth Arteche Lantegi Elkartea (BME:ART) just delivered its half-year financial results, and the numbers are tough to ignore. For the six months ended June 2025, the company saw sales climb to €244.23 million from €212.39 million year-on-year, while net income more than doubled to €19.91 million. EPS also jumped sharply. This kind of operational progress usually sparks a lot of conversation among investors who want to gauge...

Prodigy Gold NL ( ASX:PRX ) insiders who bought shares over the past year were rewarded handsomely last week. The stock...

If you have been eyeing Smart Digital Group (NasdaqCM:SDM), this week’s flurry of activity may be the nudge you were waiting for. The company’s recent Nasdaq debut caught plenty of attention, but what is keeping the momentum alive is a mix of robust early revenue numbers and ongoing buzz over its plans for an AI-driven marketing platform. With investors watching the Asia-Pacific digital ad market heat up, SDM’s drive to expand in the region and its fresh injection of capital are setting the...

SeSa S.p.A. reported first-quarter results for the period ended July 31, 2025, with sales rising to €829.14 million and net income increasing to €21.58 million compared to the prior year. Alongside its results, SeSa reaffirmed its full-year 2026 guidance, citing steady progress on its industrial plan and a commitment to its previously outlined growth and profit targets. We'll consider how SeSa's reconfirmed revenue and profit outlook following its first-quarter earnings update impacts its...

We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many...

If you’ve been tracking Black Rock Coffee Bar (BRCB), you might have noticed the company quietly inching past headlines lately. While there hasn't been a single seismic event to jolt investors, the recent trading patterns have turned some heads. On the surface, the moves are subtle, with no bombshell announcements or abrupt surges. Still, even small shifts can spark bigger questions about where the value lies and what the market is forecasting for this growing player in the coffee...

If you are watching Apollo Silver (TSXV:APGO), the company’s latest mineral resource update for its Calico Project deserves your attention. For the first time, Apollo included barite and zinc, both classified as critical minerals in the United States, alongside its silver and gold estimates. This broadens the project’s scope and, potentially, shifts market expectations. This expanded resource base could open up new developmental and economic possibilities, just as the company prepares for an...

Biogen recently announced that the U.S. FDA accepted its investigational new drug application for BIIB142, an IRAK4 degrader developed in collaboration with C4 Therapeutics, for the treatment of autoimmune diseases. This regulatory milestone highlights C4 Therapeutics’ expertise in targeted protein degradation and the momentum in its partnerships, which are advancing clinical-stage candidates. We'll explore how Biogen's progress with BIIB142 influences C4 Therapeutics' investment narrative...

Sanlorenzo S.p.A. announced its earnings for the half year ended June 30, 2025, reporting net income of €46.63 million compared to €43.58 million a year earlier. This release highlighted a year-over-year increase in profits, reinforcing ongoing user interest in Sanlorenzo’s underlying financial performance. We’ll examine how Sanlorenzo’s profit growth shapes its investment narrative and the outlook for sustained earnings and market expansion. Rare earth metals are the new gold rush. Find out...

Microbot Medical recently announced that the FDA has granted 510(k) clearance for its LIBERTY® System, making it the first single-use, remotely operated robotic device approved for peripheral endovascular procedures in the U.S., and revealed plans to raise up to US$92.2 million in gross proceeds through the exercise of preferred investment options to support commercialization and further product development. This dual milestone both enables commercial launch of a novel medical technology and...

It has been an interesting week for Ares Capital (ARCC) as the company posted a sharp decline in its stock price, dropping over 4% at a time when both the S&P 500 and Nasdaq posted gains. This pullback happened just days after Ares Capital announced the issuance of $650 million in 5.1% notes due 2031, signaling a significant move in its capital structure. The borrowing is intended to repay outstanding debt and leave room for future investments, but the combination of a new bond offering and a...

Sequans Communications (NYSE:SQNS) is making waves among investors after announcing a 1-for-10 stock split set for September 17, 2025. If you are assessing your portfolio or considering an entry, this event may have just put Sequans Communications onto your radar. While a stock split does not change the company’s fundamentals, it can influence investor sentiment and often brings about shifts in trading behavior as the share count and price per share are realigned. Stepping back from the...